Feb. 21 at 6:33 PM
$CUE On Feb 17, Cue Biopharma announced new preclinical safety data for CUE-401, its lead autoimmune drug candidate. In two animal studies (mice and non-human primates), the drug was well tolerated with no adverse events observed, including at escalating doses. Repeat dosing showed better tolerability at 1 mg/kg vs 3 mg/kg in primates. 
CUE-401 is designed to promote immune tolerance rather than suppress the immune system, using a combination of TGF-beta signaling and a modified IL-2 to expand regulatory T cells and reduce inflammatory immune responses. 
The company says the data supports its plan to file an IND and move CUE-401 into human trials in the coming months. 
Bottom line: encouraging early safety data that advances CUE-401 toward clinical trials, though it is still in the preclinical stage.
